Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Jan;65(1):133-5.
doi: 10.1038/bjc.1992.26.

A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid

Affiliations
Free PMC article
Clinical Trial

A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid

J H Anderson et al. Br J Cancer. 1992 Jan.
Free PMC article

Abstract

Recent clinical trials have suggested that a combination of folinic acid and 5-fluorouracil (5-FU) may improve response rates and survival in patients with advanced colorectal cancer. However, this regimen has been complicated by potentially life threatening toxicity. Regional delivery of folinic acid via a hepatic artery catheter might be expected to reduce systemic exposure and subsequent adverse effects. The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU. The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05). Regional folinic acid was therefore associated with a statistically significant reduction in systemic exposure compared with the intravenous route.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Adv Exp Med Biol. 1988;244:185-92 - PubMed
    1. J Clin Oncol. 1989 Oct;7(10):1407-18 - PubMed
    1. Br J Cancer. 1989 Dec;60(6):807-8 - PubMed
    1. J Clin Oncol. 1988 Jul;6(7):1184-91 - PubMed
    1. Clin Pharm. 1988 Jan;7(1):52-8 - PubMed

MeSH terms